Nanophoria
↗Milan, Italy
Nanophoria is a preclinical-stage biotechnology company pioneering a non-viral, lung-to-heart drug delivery platform. The company utilizes proprietary inorganic calcium-phosphate nanoparticles to deliver biologics, such as peptides and RNAs, directly to the heart via inhalation, aiming to treat chronic cardiovascular conditions with high precision and minimal systemic side effects.
Founded as a spin-off from Italy's National Research Council (CNR), Nanophoria is currently advancing its lead candidate, NP-MP1, for the treatment of Heart Failure with reduced Ejection Fraction (HFrEF). The company's technology represents a paradigm shift in cardiovascular medicine by enabling non-invasive, tissue-directed delivery of potent therapeutic molecules that were previously difficult to target to the heart.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cardiovascular Therapeutics
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$115M
Investors:XGEN Venture, Sofinnova Partners, CDP Venture Capital, Panakès Partners, European Innovation Council (EIC) Fund
PIPELINE
Stage:Preclinical
Lead Drug Stage:IND-enabling
Modalities:Peptide, RNA, Nanoparticle
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:National Research Council (CNR) - Scientific and technology partner, European Innovation Council (EIC) - Funding and regulatory support
COMPETITION
Position:Emerging
Competitors:Tenaya Therapeutics, Rocket Pharmaceuticals, BioAge Labs, Braveheart Bio, Affinia Therapeutics
LEADERSHIP
Key Executives:
Claudio De Luca - CEO
Federica Mancini - Head of R&D
Scientific Founders:Daniele Catalucci, Michele Iafisco, Alessio Alogna
Board Members:Suman Shirodkar (Chair), Michael H. Davidson, Paolo Fundarò, Lucia Faccio
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nanophoria. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.